NervMyo Therapeutics has developed and validated a nanoparticle-based drug delivery system for local, sustained release of insulin-like growth factor 1 (IGF-1) to enhance nerve regeneration and preserve muscle integrity following peripheral nerve injury. While the peripheral nervous system has an innate regenerative potential, functional recovery after injury is often poor due to the slow pace of regeneration. IGF-1 promotes nerve regeneration by accelerating nerve growth, yet its clinical application has been limited by challenges in achieving sustained, localized delivery. Our proprietary drug delivery system encapsulates bioactive IGF-1 with high loading efficiency, providing effective local tissue concentrations while minimizing systemic exposure. We have demonstrated robust efficacy in both small and large animal models and are now positioned to advance into the safety studies required for clinical testing. With no FDA-approved therapeutics currently available to accelerate peripheral nerve regeneration, our technology has first-to-market potential and is designed to integrate seamlessly with existing surgical techniques and nerve repair devices. With a clinically validated target and years of rigorous rodent and non-human primate data, NervMyo Therapeutics is positioned to transform the standard of care for nerve injury repair.